肝肾综合征的最新进展
Updates on Hepato-Renal Syndrome.
作者信息
Fukazawa Kyota, Lee H Thomas
机构信息
Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, NY, USA.
出版信息
J Anesth Clin Res. 2013 Sep 27;4(9):352. doi: 10.4172/2155-6148.1000352.
Abstract
Hepato-renal syndrome (HRS) is one of the most detrimental conditions in patients with end stage liver failure. Historically, HRS was considered a terminal disease associated with cirrhosis and was termed "liver-death syndrome". Furthermore, despite the improved understanding of pathophysiology and the reversibility of renal dysfunction in HRS, mortality remains extremely high especially for type 1 HRS. This review summarizes the recent advances in the pathophysiology, diagnosis and management of HRS and also provides an evolving area of research in the pathophysiologic mechanisms of HRS, which may open the door for new therapeutic approaches.
摘要
肝肾综合征（HRS）是终末期肝衰竭患者最严重的病症之一。从历史上看，HRS被认为是一种与肝硬化相关的终末期疾病，被称为“肝死亡综合征”。此外，尽管对HRS的病理生理学和肾功能障碍的可逆性有了更好的理解，但死亡率仍然极高，尤其是1型HRS。本综述总结了HRS在病理生理学、诊断和管理方面的最新进展，并提供了HRS病理生理机制中一个不断发展的研究领域，这可能为新的治疗方法打开大门。
相似文献
1
Updates on Hepato-Renal Syndrome.肝肾综合征的最新进展
J Anesth Clin Res. 2013 Sep 27;4(9):352. doi: 10.4172/2155-6148.1000352.
2
New Developments in Hepatorenal Syndrome.肝肾综合征的新进展。
Clin Gastroenterol Hepatol. 2018 Feb;16(2):162-177.e1. doi: 10.1016/j.cgh.2017.05.041. Epub 2017 Jun 7.
3
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.肝性肾病综合征的病理生理学、定义和分类的新进展：超越国际腹水俱乐部（ICA）共识文件的一步。
J Hepatol. 2019 Oct;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11.
4
Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.重新评估肝硬化患者 AKI 和肝肾综合征的谱。
Nat Rev Nephrol. 2020 Mar;16(3):137-155. doi: 10.1038/s41581-019-0218-4. Epub 2019 Nov 13.
5
[Paradigm shift in understanding Acute kidney injury in patients with chronic liver disease: From pathophysiology to defining disease entities].[慢性肝病患者急性肾损伤认识的范式转变：从病理生理学到疾病实体的定义]
Z Gastroenterol. 2020 Mar;58(3):254-266. doi: 10.1055/a-1088-1582. Epub 2020 Mar 20.
6
Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs.肝肾综合征的病理生理学、诊断及临床管理：从经典药物到新药
Curr Vasc Pharmacol. 2014 Jan;12(1):125-35. doi: 10.2174/157016111201140327163930.
7
Recent advances in the management of hepato-renal syndrome (HRS).肝肾综合征（HRS）治疗的最新进展。
Acta Clin Belg. 2007;62 Suppl 2:393-6. doi: 10.1179/acb.2007.088.
8
[Hepato-renal syndrome].
G Ital Nefrol. 2017 Mar;34(Suppl 69):178-187.
9
Renal interactions in liver dysfunction and failure.肝功能障碍和衰竭中的肾脏相互作用。
Curr Opin Crit Care. 2013 Apr;19(2):133-41. doi: 10.1097/MCC.0b013e32835ebb3a.
10
Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome.肝肾综合征的流行病学、病理生理学和治疗。
Semin Nephrol. 2019 Jan;39(1):17-30. doi: 10.1016/j.semnephrol.2018.10.002.
引用本文的文献
1
Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost.肝肾综合征的早期诊断及及时使用特利加压素可改善预期结局并降低成本。
Clinicoecon Outcomes Res. 2025 Aug 29;17:615-625. doi: 10.2147/CEOR.S530832. eCollection 2025.
2
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges.儿童重大疾病中的肝肾相互作用：解析复杂性与临床挑战
J Clin Med. 2025 Jun 2;14(11):3911. doi: 10.3390/jcm14113911.
3
Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.特利加压素治疗肾功能快速下降的肝肾综合征成人患者的相关治疗费用分析。
Adv Ther. 2023 Dec;40(12):5432-5446. doi: 10.1007/s12325-023-02674-z. Epub 2023 Oct 9.
4
Fucoidan alleviates the hepatorenal syndrome through inhibition organic solute transporter α/β to reduce bile acids reabsorption.岩藻依聚糖通过抑制有机溶质转运体α/β减轻肝肾综合征，以减少胆汁酸重吸收。
Curr Res Pharmacol Drug Discov. 2023 Jun 22;5:100159. doi: 10.1016/j.crphar.2023.100159. eCollection 2023.
5
Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy.非酒精性脂肪性肝病与糖尿病肾病之间潜在基因相互作用的综合分析。
Front Endocrinol (Lausanne). 2022 Oct 25;13:1032814. doi: 10.3389/fendo.2022.1032814. eCollection 2022.
6
Research Progress and Treatment Status of Liver Cirrhosis with Hypoproteinemia.肝硬化合并低蛋白血症的研究进展与治疗现状
Evid Based Complement Alternat Med. 2022 Feb 24;2022:2245491. doi: 10.1155/2022/2245491. eCollection 2022.
7
High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes.高 FIB4 指数是 2 型糖尿病患者糖尿病肾病的独立危险因素。
Sci Rep. 2021 Jun 3;11(1):11753. doi: 10.1038/s41598-021-88285-6.
8
Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions.器官串扰：炎症和纤维化变化在器官相互作用过程中的有力作用。
Inflamm Res. 2019 Oct;68(10):825-839. doi: 10.1007/s00011-019-01271-7. Epub 2019 Jul 20.
9
Acute kidney injury in children with chronic liver disease.儿童慢性肝脏疾病中的急性肾损伤。
Pediatr Nephrol. 2019 Jan;34(1):45-59. doi: 10.1007/s00467-018-3893-7. Epub 2018 Mar 1.
10
Liberation From Renal Replacement Therapy After Cadaveric Liver Transplantation.尸体肝移植后摆脱肾脏替代治疗
Transplant Direct. 2016 Oct 10;2(11):e110. doi: 10.1097/TXD.0000000000000622. eCollection 2016 Nov.
本文引用的文献
1
Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications.肝硬化中的病理性细菌易位：病理生理学、诊断和临床意义。
Liver Int. 2013 Jan;33(1):31-9. doi: 10.1111/liv.12021. Epub 2012 Nov 4.
2
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.尿中性粒细胞明胶酶相关载脂蛋白预测肝硬化患者死亡率并识别急性肾损伤。
Dig Dis Sci. 2012 Sep;57(9):2362-70. doi: 10.1007/s10620-012-2180-x. Epub 2012 May 6.
3
Hepatorenal syndrome: a critical update.肝肾综合征：关键性更新。
Semin Respir Crit Care Med. 2012 Feb;33(1):55-69. doi: 10.1055/s-0032-1301735. Epub 2012 Mar 23.
4
Medical management of hepatorenal syndrome.肝肾综合征的医学治疗。
Nephrol Dial Transplant. 2012 Jan;27(1):34-41. doi: 10.1093/ndt/gfr736.
5
Hepatorenal syndrome in the intensive care unit.重症监护病房中的肝肾综合征。
J Intensive Care Med. 2013 Mar-Apr;28(2):79-92. doi: 10.1177/0885066611408692. Epub 2011 Aug 21.
6
Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.肝肾综合征患者的诊断、治疗和生存情况：日常医疗实践调查。
J Hepatol. 2011 Dec;55(6):1241-8. doi: 10.1016/j.jhep.2011.03.012. Epub 2011 Apr 13.
7
Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis.肝硬化高动力循环和中心低血容量的决定因素。
Gut. 2011 Sep;60(9):1254-9. doi: 10.1136/gut.2010.235473. Epub 2011 Apr 19.
8
Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury.肝缺血再灌注损伤后潘氏细胞衍生的白细胞介素-17A 引起多器官功能障碍。
Hepatology. 2011 May;53(5):1662-75. doi: 10.1002/hep.24253.
9
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis.工作组关于修订肝硬化患者肾功能障碍分类系统的建议。
Gut. 2011 May;60(5):702-9. doi: 10.1136/gut.2010.236133. Epub 2011 Feb 15.
10
Estimating the cost of treating patients with liver cirrhosis at the Mexican Social Security Institute.估算墨西哥社会保障研究所治疗肝硬化患者的成本。
Salud Publica Mex. 2010 Nov-Dec;52(6):493-501.
Zotero 插件